Alendronate Sodium Tablet
Product Images NDC 70518-1192

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 70518-1192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (1203dd0c 809a 4409 B948 B5e816b8a63a 01)

Chemical structure of alendronate sodium, depicted as a molecular diagram showing the arrangement of atoms including amino, hydroxyl, phosphonate, and sodium components with associated water molecules (3H2O).*

FDA Label Image

2 (1203dd0c 809a 4409 B948 B5e816b8a63a 02)

A line graph depicting the cumulative incidence of hip fractures over 36 months in a three-year study. It compares patients treated with Alendronate Sodium versus placebo, showing percentage incidence on the vertical axis and time in months on the horizontal axis. Alendronate Sodium exhibits a lower cumulative incidence than placebo throughout the study period.*

FDA Label Image

3 (1203dd0c 809a 4409 B948 B5e816b8a63a 03)

A bar chart titled 'Osteoporosis Treatment Studies in Postmenopausal women' showing mean percentage increase in bone mineral density (BMD) relative to placebo after three years of Alendronate Sodium 10 mg/day. Data is divided between U.S. and Multinational groups for lumbar spine, femoral neck, and trochanter sites with error bars representing standard error.*

FDA Label Image

4 (1203dd0c 809a 4409 B948 B5e816b8a63a 04)

A dual line graph titled 'Osteoporosis Treatment Studies in Postmenopausal Women' showing the time course effect of Alendronate Sodium 10 mg/day versus placebo on lumbar spine bone mineral density (BMD) percentage change from baseline. The left graph represents a US study and the right graph a multinational study, both plotting mean percent change in BMD over 36 months. In both graphs, Alendronate Sodium shows a positive increase in BMD over time, while placebo remains relatively unchanged.*

FDA Label Image

5 (1203dd0c 809a 4409 B948 B5e816b8a63a 05)

Two bar graphs showing osteoporosis prevention studies in postmenopausal women, illustrating change in bone mineral density (BMD) from baseline over 2-year and 3-year periods. Each graph compares BMD percent change with Alendronate Sodium 5mg/day versus placebo at four sites: lumbar spine, femoral neck, trochanter, and total body.*

FDA Label Image

6 (1203dd0c 809a 4409 B948 B5e816b8a63a 06)

A bar chart showing the increase in bone mineral density (BMD) at one year for glucocorticoid-treated patients taking Alendronate Sodium 5 mg/day. It compares mean percentage BMD increases at the lumbar spine, femoral neck, and trochanter sites between U.S. and multinational study groups, with error bars representing standard errors.*

FDA Label Image

7 (1203dd0c 809a 4409 B948 B5e816b8a63a 07)

A line graph titled 'Studies in Paget's Disease of Bone' showing the effect on serum alkaline phosphatase of Alendronate Sodium 40 mg/day versus placebo or Etidronate 400 mg/day. The graph plots percentage change from baseline on the y-axis against time in months on the x-axis, with lines representing placebo, Etidronate 400 mg/day, and Alendronate Sodium 40 mg/day from multinational and U.S. studies.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Alendronate Sodium 35 mg oral tablets, showing a quantity of 12 tablets. The label includes manufacturer info (Cipla Ltd, Kurkumbh, India) and repackager details (RemedyRepack Inc., Indiana, PA). It features dosage form, strength, barcode, NDC number, warnings to keep out of children's reach, and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.